Mode
Text Size
Log in / Sign up
N/A N=200

The Impact of SCN9A Gene Polymorphism on Individual Pain Perception in the General Population

Pain · Surgery

Enrolled (actual)
200
Serious AEs
0.0%
Results posted
Sep 2014
Primary outcome: Primary: Opioid Consumption Dose 48h After Operation. — 37.4; 50.4 microgramme

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Age
Adult, Older Adult · 20+ yrs
Sex
All
Sponsor
Xianwei Zhang
Primary completion
Dec 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Opioid Consumption Dose 48h After Operation.
37.4; 50.4
PRIMARY
PCA Press Frequency 48h After Operation.
8.8; 19.9
SECONDARY
The Visual Analog Scale 48h After Operation.
6.9; 5.0
SECONDARY
Preoperative Pressure Pain Threshold (PPT)
3.6; 3.7
SECONDARY
Preoperative Pressure Pain Tolerance (PTO)
6.6; 6.5

Summary

This study was conducted to explore whether the non-synonymous single-nucleotide polymorphisms in SCN9A gene can predict individual basal pain perception and postoperative pain intensity in the general population undergoing upper abdominal surgery. Methods: Patients receiving elective upper abdominal surgery under general anesthesia were recruited into this study. Genotyping of SCN9A was carried out by direct sequencing. The investigators measured their preoperative pressure pain threshold (PPT) and pressure pain tolerance (PTO). The visual analog scale (VAS) was used for pain evaluation at rest during patient-controlled analgesia (PCA) treatment 0 h, 12 h ,24 h and 48h after operation. And the PCA press frequency and drug consumption were recorded.

Eligibility Criteria

Inclusion Criteria

  • Aged 20-70 years
  • Receiving elective upper abdominal surgery
  • Anesthesiologists (ASA) physical status I or II
  • Received PCA administration
  • Agreed to participate the research

Exclusion Criteria

  • History of chronic pain
  • Psychiatric diseases
  • Diabetes mellitus
  • Severe cardiovascular diseases
  • Kidney or liver diseases
  • Alcohol or drug abuse
  • Heavy smoker
  • Pregnancy or at lactation period
  • Refused PCA administration
  • Disagree to participate to the research
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01507493). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search